Introduction {#s1}
============

Medication errors are common in the hospital setting and can lead to adverse drug events \[[@B1]\]. In MEDMARX, the errors reported included prescription errors (21%), medication-delivery errors (22%) and administration errors (33%) \[[@B2]\]. Administration, the final step of the medication process, has been less well studied although it directly concerns nurses and patients and is the last barrier before a possible consequence for the patient.

Administration error is defined as a deviation from the physician's medication order as written on the patient's chart \[[@B3]\]. The denominator of error rate is generally the Total Opportunity for Errors (TOE) and could be calculated according to 2 definitions but both definitions produce identical results \[[@B4]\]. First, it is defined as the sum of the total number of doses ordered plus the unordered doses given \[[@B5]\]. According to the second definition, it is the sum of the doses given plus the number of omission errors \[[@B6],[@B7]\]. The clinical impact of administration errors can be evaluated using general classification American Society of Health-system Pharmacists (ASHP) \[[@B8]\] or the National Coordinating Council for Medication Error Reporting and Prevention (NCCMERP) \[[@B1]\]. In order to detect drug administration errors, the observation technique gives more efficient, objective, and reliable results than spontaneous reporting or patient chart reviews \[[@B3],[@B9]\]. However, this technique is very time-consuming and cannot be carried out for very long periods of time. Several studies have evaluated administration errors. No systematic reviews using the observation technique have been published so far \[[@B10]--[@B16]\]. The Institute of Medicine reported an extensive review of the literature on medication errors and errors rates \[[@B17]\] but did not focus on the observation technique.

The aim of this present systematic review is to systematically analyse the published evidence concerning the prevalence, nature and severity of administration errors in hospitals detected by the observation technique.

Methods {#s2}
=======

Search strategy {#s2.1}
---------------

The following electronic databases were used: MEDLINE, EMBASE, and the Cochrane Library. Our search concerned published studies in any language from January 1966 up to December 2011 ([Figure S1](#pone.0068856.s001){ref-type="supplementary-material"}). The reference lists of all selected studies were collected for additional studies.

Inclusion and exclusion criteria {#s2.2}
--------------------------------

Studies that reported the detection of medication errors using the observation method \[[@B18]\], and the rate of administration errors among hospital inpatients were included. Cross-sectional, prospective, and intervention studies that evaluated intervention to reduce errors (before-and-after, randomized controlled) were included. Retrospective studies, abstracts, letters to editors, studies in nursing homes, and studies which evaluated errors for only one drug class were excluded. Administration errors could be detected using spontaneous reporting, review of patient charts or observation. Reporting systems suppose that the person reporting is aware that an error was made. Reviewing patient charts is time consuming \[[@B19]\]. Observation method is considered to be the standard for error detection as it yields more objective and reliable results \[[@B3],[@B9],[@B20]\]. Briefly, an observer follows the nurse giving the medications and notes the administration of each dose. The notes are then compared with the prescription. An error is counted when the nurse does not carry out the order accurately. Results are presented using the TOE or the doses observed as the denominator for error rate.

Study selection and data abstraction {#s2.3}
------------------------------------

Two reviewers (senior pharmacists) screened the title and abstract of each publication to independently determine eligibility. They screened the full text of the articles and extracted the main outcome independently. One reviewer extracted the data; the second reviewer checked the data. Discrepancies were resolved by consensus between the two reviewers after discussion. If no consensus was achieved, a third researcher arbitrated. Standardised data-extraction forms were used to extract relevant data on inclusion criteria (study design, year and country, study period, hospital setting), methods (sampling, profession of observers, number of observers, definitions used), and the rate, type, and severity of administration errors. Error rates were extracted in the control period for crossover-studies, before intervention for before-and-after studies, and in all groups in the control period in randomized controlled before-after studies (we estimated that during each study, practices may change even in the control groups after intervention). For studies that presented results as the doses observed, authors were contacted for further information so that their results could be expressed as TOE. If the authors had clarified the denominator used, we re-evaluated data with TOE. Types of errors were reclassified according to the ASHP classification \[[@B8]\]: omission error (the failure to administer an ordered dose to a patient before the next scheduled dose, if any), wrong time error (administration of medication outside a predefined time interval from its scheduled administration time (this interval should be established by each individual health care facility)), unauthorized drug error (administration to the patient of medication not authorized by a legitimate prescriber for the patient), wrong dose error (administration to the patient of a dose that is greater than or less than the amount ordered by the prescriber or administration of duplicate doses to the patient, i.e., one or more dosage units in addition to those that were ordered), wrong dosage-form error (administration to the patient of a drug product in a different dosage form than ordered by the prescriber), wrong drug-preparation error (drug product incorrectly formulated or manipulated before administration), wrong administration technique error (inappropriate procedure or improper technique in the administration of a drug), deteriorated drug error (use of expired drugs or improperly stored drugs) and other medication error (including any drug administration errors not fitting into the predefined categories). The ASHP classification did not specify the time limits used to determine a wrong time error: generally 30 or 60 minutes before or after the scheduled prescription time \[[@B21]\]. Authors \[[@B3]\] recommended that studies on medication errors should report both the errors rate with and without timing error as clinicians often consider wrong time error to be minor. Studies that reported clinical impact were analyzed and impact was reclassified by the two reviewers into 4 main categories (fatal, life-threatening, significant, minor or no impact) when possible. Discrepancies were resolved by consensus between the two reviewers after discussion.

Risk of bias or quality of reporting {#s2.4}
------------------------------------

We assessed the quality of reporting of the studies using an evaluation scale adapted from the STROBE Statement checklist \[[@B22]\]. Each item was filled by one reviewer and was validated by the second reviewer.

Main outcomes {#s2.5}
-------------

The main outcome was the error rate without wrong time errors and measured at the study level. The secondary outcomes were the error rate including wrong time errors at 60 minutes and clinical impact of errors.

Studies were analyzed separately for administration doses observed and TOE, and according to study designs except for a subgroup exploratory analysis. Egger et al. recommend the results from randomized control trials (RCTs) and non-randomized control trials (non-RCTs) to be stratified to explore potential heterogeneity due to study designs \[[@B23]\].

The global error rate was calculated for each study as the number of errors (or the number of administration with at least one error) divided by the TOE or the doses observed (multiplied by 100). We chose to present the results with the number of errors as numerator, as the studies presenting the number of administration also presented the number of errors. When the number of errors exceed the number of observations (Zribi Triki \[[@B24]\], Gokhman \[[@B25]\]), we modified the numerator to be equal to the denominator. For each study (when available), we also calculated the error rate by type of error using the number of errors of the considered type in the numerator (and the TOE or doses observed in denominator). In a subgroup exploratory analysis, we compared the error rates in studies evaluating injectable drugs only and oral drugs only; and error rates in intensive care units only versus other units.

Statistical analyses {#s2.6}
--------------------

Given the heterogeneity within the review, we did not undertake a formal meta-analysis. The results were reported using the median error rate across the studies with interquartile range (IQR). The median for the global error rate corresponds to the error rate above which (or equivalently below which) 50% of the studies lie for their observed global error rate. The median for the error rate for a particular type corresponds to the error rate above which (or equivalently below which) 50% of the studies lie for their observed error rate for this particular type (considering only studies reporting this type of error). Heterogeneity was presented using the Cochran Q Chi-squared test and Higgins' and Thompsons' I^2^ statistic. A value of 0% indicates no observed heterogeneity, and larger values show increasing heterogeneity. I^2^ values greater than 75% with low P values from the Cochran Q test were considered as indicating substantial heterogeneity. To study the publication bias, we plotted the study precision (within-study standard error) against the log-odds of error rate without wrong time errors (funnel plot). If studies with large proportions of errors were less likely to be published, the funnel plot would appear asymmetric about the vertical. Funnel plot asymmetry was assessed using Egger's test \[[@B26]\]. Under the null hypothesis of no small study effects, the regression line of the effect against its standard error would be vertical.

The software R was used for forest plots (version 2.12.0); the software Stata was used for funnel plots (StataCorp. 2009. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP; commands "metareg" and "metabias"); and the software SAS was used for descriptive statistics (version 9.2; SAS Institute Inc., Cary, NC, USA). The analysis conformed to the PRISMA checklist ([Table S1](#pone.0068856.s003){ref-type="supplementary-material"}).

Results {#s3}
=======

The electronic search initially identified 2088 publications. After screening titles and abstracts, 1967 publications did not meet the inclusion criteria. The remaining 121 publications were obtained in full text and assessed for suitability. Searching of the reference lists of the included publications identified one other study, published before 1966, that was eligible as well as six other publications. Overall, 66 publications were included \[[@B6],[@B7],[@B10]--[@B16],[@B18],[@B24],[@B25],[@B27]--[@B80]\] ([Figure 1)](#pone-0068856-g001){ref-type="fig"}.

![Flow diagram of the screening process.](pone.0068856.g001){#pone-0068856-g001}

Characteristics of included studies {#s3.1}
-----------------------------------

The details of the 66 studies are presented in [Table S2](#pone.0068856.s004){ref-type="supplementary-material"} (studies classified by denominator). They were cross-sectional studies (N=46, 70%), before-and-after studies (N=16, 24%), RCTs (N=2, 3%), controlled before-and-after study (CBAs) (N=1, 2%), and cross-over study (N=1, 2%). None of the studies met all 15 quality of reporting assessment criteria ([Table 1)](#tab1){ref-type="table"}.

###### Number of studies with information reported in the text.

  General items                  Items                                                                 Number of studies describing the item (%) N=66
  ------------------------------ --------------------------------------------------------------------- ------------------------------------------------
  Nurse                          Selection method of observed nurses                                   24 (36.4)
                                 Number of observations per nurse                                      5 (7.6)
                                 Selection method of observation period                                12 (18.2)
                                 Number of observed nurses                                             28 (42.4)
                                 Total number of nurses in the ward or during the observation period   12 (18.2)
                                 Nurse practice experience                                             23 (34.8)
                                 Nurse aware (or not) of the aim of the study                          49 (74.2)
  Route of drug administration   IV, oral or both                                                      59 (89.4)
  Patients                       Number of patients                                                    34 (51.5)
  Observation method             Error definition                                                      57 (86.4)
                                 Type and number of observers                                          62 (93.9)
                                 Training of observers                                                 40 (60.6)
                                 Classification of administration errors defined                       57 (86.4)
                                 DO or TOE^[a](#ngtab1.1)^ identified                                  66 (100.0)
                                 Clinical impact evaluated                                             32 (48.5)

DO: doses observed, TOE: Total Opportunity for Errors. Error rate was reported to be calculated using doses observed in 23 publications. After contacting the authors, the denominator definition was confirmed for 5 studies, was declared to be TOE for 9 studies, and remained unanswered for 9 studies. Overall, we identified 14 publications using the doses observed to calculate the error rate and 52 using TOE.

Types of errors {#s3.2}
---------------

For 23 publications, the doses observed was used as denominator to calculate the error. After contacting the authors, the denominator definition was confirmed for 5 studies, was declared to be TOE for 9 studies, and remained unanswered for 9 studies. Overall, we analyzed 14 publications using the doses observed and 52 using TOE. Types of errors could not be extracted for 4 studies: Greengold \[[@B45]\] (not including wrong time errors), Dean \[[@B37]\] (not including wrong time errors), Hynniman \[[@B6]\] and Schnell \[[@B7]\] for which only the number of wrong time errors could be extracted. Wrong time errors and wrong drug-preparation errors were the most frequent types of errors ([Table 2)](#tab2){ref-type="table"}.

###### Types and rates of administration errors.

  Types of errors (ASHP)^[a](#ngtab2.1)^   Number of studies^[c](#ngtab2.2)^ (TOE^[b](#ngtab2.3)^)   N (TOE)   Median Rate (%) \[Q1-Q3\]^[d](#ngtab2.4)^ (TOE)   Number of studies^[c](#ngtab2.2)^ (DO^[b](#ngtab2.3)^)   N (DO)   Median Rate (%) \[Q1-Q3\]^[d](#ngtab2.4)^ (DO)
  ---------------------------------------- --------------------------------------------------------- --------- ------------------------------------------------- -------------------------------------------------------- -------- ------------------------------------------------
  omission                                 42                                                        69623     1.6 \[0.8-4.1\]                                   9                                                        4534     1.6 \[0.8-2.8\]
  wrong-time error^[e](#ngtab2.5)^         41                                                        86525     4.4 \[1.3-16.1\]                                  8                                                        9839     7.2 \[1.8-12.6\]
  wrong-time error (30mn)                  7                                                         5908      26.9 \[9.2-31.4\]                                 1                                                        572      1.57
  wrong-time error (60mn)                  22                                                        44497     5.4 \[1.9-15.0\]                                  4                                                        7412     8.6 \[7.2-13.0\]
  unauthorized drug error                  42                                                        72339     0.3 \[0.1-0.8\]                                   12                                                       11576    0.7 \[0.2-1.6\]
  wrong dose error                         47                                                        78164     1.4 \[0.7-3.4\]                                   12                                                       11576    3.2 \[2.6-5.2\]
  wrong dosage-form error                  31                                                        54036     0.1 \[0.0-0.3\]                                   6                                                        9884     0.5 \[0.2-0.8\]
  wrong drug-preparation error             30                                                        49912     2.1 \[0.1-6.2\]                                   8                                                        6893     8.6 \[3.3-30.3\]
  wrong administration technique error     43                                                        74820     1.2 \[0.03-3.5\]                                  13                                                       12261    4.1 \[1.8-14.6\]
  deteriorated drug error                  19                                                        33161     0.1 \[0.0-0.8\]                                   2                                                        317      0.7 \[0.0-1.4\]
  other medication error                   24                                                        50402     1.4 \[0.4-3.5\]                                   3                                                        1167     0.8 \[0.6-3.3\]

^a^ Types of errors could not be extracted for 4 studies (Greengold \[45\], Dean \[37\] and Hynniman \[6\], Schnell \[7\] except for wrong time errors).

DO: doses observed, TOE: Total Opportunity for Errors.

Number of studies considering the error type (among the 52 studies with TOE and 14 studies with doses observed).

Wrong time errors evaluated for 49 studies (41 TOE and 8 studies using doses observed). Among these 49 studies, 15 did not specify the wrong time delay and therefore were not analysed.

Median rate for the studies considering the error type \[First Quartile -- Third Quartile\]. Unit of analysis for the median was the study that is 50% of the studies had an observed error rate greater (or lower) than the median rate reported.

Error unit {#s3.3}
----------

### Error rate without wrong time errors {#s3.3.1}

For the publications using TOE ([Figure 2)](#pone-0068856-g002){ref-type="fig"}, the median error rates without wrong time errors were 10.5% \[IQR: 7.3%-21.7%\] for the 34 cross-sectional studies, 6.9% \[IQR: 3.6%--10.3%\] for the 15 before-and-after studies, 7.5% and 8.3% for the 2 RCT studies, and 6.8% for the cross-over study. There was a considerable heterogeneity among the 34 cross-sectional studies (Q=6205.2, *p*\<0.001, I^2^= 99.5%) and the 15 before-and-after studies (Q=785.0, *p*\<0.001, I^2^= 98.2%), whereas the heterogeneity was not as apparent among the 2 RCT studies (Q=1.5, *p*=0.23, I^2^= 30.9%). There was no obvious asymmetry in the funnel plot suggesting no evidence of publication bias (Egger's test: *p*=0.57) (Figure S2/A).

![Forest plots for error rate (95%CI) without wrong time errors (TOE).](pone.0068856.g002){#pone-0068856-g002}

For the publications using doses observed ([Figure 3)](#pone-0068856-g003){ref-type="fig"}, the median error rates without wrong time errors were 19.7% \[IQR: 9.2%-55.6%\] for the 12 cross-sectional studies, 9.9% for the before-and-after study, and 4.8% for the controlled before-and-after study. There was a considerable heterogeneity among the 12 cross-sectional studies (Q=2386.4, *p*\<0.001, I^2^= 99.5%). There was no obvious asymmetry in the funnel plot suggesting no evidence of publication bias (Egger's test: *p*=0.84) (Figure S2/B).

![Forest plots for error rate (95%CI) without wrong time errors (doses observed).](pone.0068856.g003){#pone-0068856-g003}

Wrong time errors were analysed in 49 studies of the 66 studies. Among these studies, 26 studies defined the wrong time delay as 60 minutes, 8 as 30 minutes and the 15 other studies (Schnell \[[@B7]\], Hynniman \[[@B6]\], Borel \[[@B31]\], Bourlon \[[@B32]\], Conroy \[[@B36]\], Haw \[[@B48]\], Font Noguera \[[@B40]\], Ghaleb \[[@B44]\], Gokhman \[[@B25]\], Rodriguez-González \[[@B65]\], Schneider \[[@B69]\], Helmons \[[@B49]\], Paoletti \[[@B57]\], Teixeira \[[@B72]\], Zribi Triki \[[@B24]\]) did not specify the wrong time delay. These 15 studies were not included in the further analyses.

### Error rate including wrong time errors at 60 minutes {#s3.3.2}

For the publications using TOE ([Figure 4)](#pone-0068856-g004){ref-type="fig"}, the median error rates including wrong time errors were respectively 25.2% \[IQR: 12.1%-38.4%\] (N=15) for the cross-sectional studies, and 22.5% \[IQR: 7.2%--23.8%\] (N=7) for the before-and-after studies. For the publications using doses observed ([Figure 5)](#pone-0068856-g005){ref-type="fig"}, the median error rates including wrong time errors were respectively 11.8%, 12.9% and 28.0 for the 3 cross-sectional studies, and 19.8% for the before-and-after study. Analyses with wrong time delay at 30 minutes are on demand.

![Forest plots for error rate (95%CI) including wrong time errors at 60 minutes (TOE).](pone.0068856.g004){#pone-0068856-g004}

![Forest plots for error rate (95%CI) including wrong time errors at 60 minutes (doses observed).](pone.0068856.g005){#pone-0068856-g005}

### Exploratory analysis for studies using TOE {#s3.3.3}

For this exploratory analysis, we excluded studies evaluating both injectable and oral drugs, and studies where the type of unit was unknown or where the units were mixed (medical, surgical and intensive care). Concerning the route of administration, 4 studies evaluated only injectable drugs. The median error rate without wrong time errors was 9.8% \[min-max: 6.8%-26.6%\]. For the 5 studies evaluating only oral drugs, the median error rate without wrong time errors was 5.5% \[min-max: 4.0%-16.7%\]. Concerning the characteristics of the unit, 8 studies evaluated error rate in intensive care units. The median error rate without wrong time errors was 9.1% \[IQR: 3.4%-19.9%\]. For the 33 studies evaluating errors in other units, the median error rate without wrong time errors was 8.6% \[IQR: 6.8%-16.7%\].

Clinical impact {#s3.4}
---------------

Clinical impact of errors was specified in 48% of the studies (32 studies). For 18 studies, we could reclassify the data in 4 main categories (fatal, life-threatening, significant, minor, or no impact) ([Table S3](#pone.0068856.s005){ref-type="supplementary-material"}) \[[@B11],[@B12],[@B14],[@B15],[@B35],[@B48],[@B52],[@B53],[@B58]--[@B60],[@B65],[@B70],[@B75]--[@B78],[@B80]\]. No fatal error was observed. In the 14 other studies, most of errors were classified as minor.

Discussion {#s4}
==========

We found 66 studies which reported the rate of administration errors detected by the observation method. These studies presented different study designs and did not report the error rate using the same unit for the denominator (TOE or doses observed). In addition these studies did not consider all 9 types of errors from the ASHP, such as wrong time errors. We therefore did not perform a formal meta-analysis. Most of the studies were cross-sectional studies (N=46, 70%). The median error rates without wrong time errors reached 10.5% for the 34 cross-sectional studies using TOE and 19.7% for the 12 cross-sectional studies using doses observed. Median error rates tended to be lower for interventional studies (RCT studies, before-and-after studies, cross-over study).

Clinical impact was evaluated for 32 studies (48%) and classification was heterogeneous. No fatal error was observed and most of the errors observed were minor.

To our knowledge, this is the first systematic review of administration errors detected by the observation method. In a review, Ghaleb \[[@B81]\] identified 32 studies reporting the incidence of medication error, of which 8 concerned drug-administration errors detected by observation. Error rates varied from 0.6% to 27% of administrations but the study selection was not exhaustive. Miller \[[@B82]\] conducted a systematic literature review on medication errors for children between 2000 and 2005; 14 studies evaluated administration errors and none of them used the observation method to determine error. The only study \[[@B83]\] using TOE for error rate showed an administration error rate of 23.5%.

The extreme heterogeneity of studies definitions (definition of error rate with number of errors or number of administrations with at least one error, TOE or doses observed, error classification) is well known \[[@B17]\]. That is why we focused on one error identification methodology (direct observation). But heterogeneity was also found within this methodology. A major source of the high heterogeneity between studies could be the calculation of error rate. The types of errors considered in many studies did not use the ASHP classification and these studies therefore did not consider all possible types of errors. As a consequence, the definition of error rates (numerator and denominator) varied according to the study, in particular the definition of wrong time error. However, the definition of the error rate without wrong time errors remained heterogeneous among the studies because they did not consider all other types of errors. These other types of errors seemed to be less reported because they were less frequent. For example, deteriorated drug errors (use of expired drugs or improperly stored drugs) were reported in only 28% of studies using TOE but the median error rate in these studies was only 0.1%.

Our review has some limitations.

We selected studies in which the observation method, either disguised or undisguised, was used to detect drug errors. The disguised observation may be the gold standard to evaluate error rate. However, the information whether the observation was disguised or not was available in only 49 studies (74% of the studies included). There was no evidence of difference between the two types of observation method.

Important characteristics such as the type of units and the route of administration of drugs (injectable and oral) could only be evaluated in an exploratory analysis as the number of studies was too small. However, there did not seem to have difference in the error rates in different subgroups.

We used an evaluation scale adapted from the STROBE Statement checklist \[[@B22]\] to evaluate whether information was reported. However, no conclusion was made as to whether it was done appropriately in the study. We investigated the presence of publication bias using funnel plots. These analyses indicated there was no evidence of publication bias, despite that publication bias in a review may not always result in an asymmetrical funnel plot \[[@B84]\].

The calculation of error rate was not homogenous: some authors used the number of errors and others used the number of administrations with at least one error. We only presented the results with the first definition (number of errors) as most of the studies presented this type of rate. Authors described the number of errors by type and calculated the error rate without wrong time error by subtracting the number of wrong time errors from the total number of errors. When the number of errors exceeded the number of observations, we evaluated that the error rate reached 100%. The error rate appeared high even when it did not include wrong time errors. Information on how serious these errors were and the rigor of error definition was not available in all of the publications that we selected.

Standardization of administration error rate using the same denominator (TOE) and types of errors remains essential for further publications. To calculate an error rate, we recommend excluding some types of errors, and reporting the number of administrations (TOE) with at least one error and the number of errors and their types according to ASHP classification (9 types). We also advise reporting of the time limits used to determine wrong time errors. If the study implicates an evaluation of medication process, we recommend distinguishing the error rate per process (order, dispensing, and preparation/administration). Finally, the characteristics of hospital need to be presented (country, types of units, delivery system, characteristics of nurses observed).

We did not evaluate interventions to improve administration errors which are important pieces of information for the clinician. The Canadian Agency for Drugs and Technologies in Health \[[@B85]\] and the US Agency for Healthcare Research and Quality \[[@B86]\] recommend the use of technologies to reduce administration errors. This may include improving the dispensing process with an automated bedside dispensing machine or unit-dose dispensing, or improving the administration process by using dedicated medication nurses with specific training, education on drug safety, medication charts, or a bar-code medication administration system. The impact of these technologies needs to be more evaluated.

In summary, administration errors are frequent among inpatients. The median error rate without wrong time errors for the cross-sectional studies using TOE was about 10%. No fatal error was observed and most errors were classified as minor in the 18 studies in which clinical impact was analyzed. We did not find any evidence of publication bias. A standardization of administration error rate using the same denominator (TOE), numerator and types of errors is essential for further publications.
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